Natixis Advisors LLC Has $27.61 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Natixis Advisors LLC grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 10.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 338,924 shares of the medical equipment provider's stock after buying an additional 31,436 shares during the quarter. Natixis Advisors LLC owned about 0.15% of Hologic worth $27,609,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Coastline Trust Co acquired a new position in shares of Hologic during the 3rd quarter valued at $118,000. Empowered Funds LLC grew its holdings in Hologic by 8.8% during the third quarter. Empowered Funds LLC now owns 3,603 shares of the medical equipment provider's stock worth $294,000 after acquiring an additional 291 shares during the period. Empirical Finance LLC lifted its holdings in Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider's stock valued at $690,000 after acquiring an additional 147 shares during the last quarter. CIBC Asset Management Inc boosted its position in shares of Hologic by 7.9% during the 3rd quarter. CIBC Asset Management Inc now owns 33,973 shares of the medical equipment provider's stock valued at $2,767,000 after purchasing an additional 2,483 shares in the last quarter. Finally, OneDigital Investment Advisors LLC grew its stake in shares of Hologic by 5.4% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 7,075 shares of the medical equipment provider's stock worth $576,000 after purchasing an additional 360 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HOLX has been the subject of several recent research reports. UBS Group raised their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Raymond James boosted their target price on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. Mizuho cut their price objective on Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Tuesday, November 5th. Finally, Stephens reiterated an "overweight" rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, Hologic currently has a consensus rating of "Moderate Buy" and an average target price of $89.91.

Hologic Stock Up 0.3 %

Shares of NASDAQ HOLX traded up $0.26 during trading hours on Tuesday, hitting $79.05. The stock had a trading volume of 795,389 shares, compared to its average volume of 1,587,878. The company has a market capitalization of $18.36 billion, a P/E ratio of 23.66, a P/E/G ratio of 2.48 and a beta of 0.98. The firm's 50-day moving average price is $80.63 and its two-hundred day moving average price is $78.28. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 52 week low of $67.59 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the firm posted $0.89 EPS. The firm's revenue for the quarter was up 4.5% on a year-over-year basis. Analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.